Studies on BPTF: Potential Drug Target for Alzheimer's (G2186)

Target Name: BPTF

NCBI ID: G2186

BPTF

Studies on BPTF: Potential Drug Target for Alzheimer's

BPTF (fetal Alzheimer's reactive clone 1) is a protein that is expressed in the brain and has been identified as a potential drug target for Alzheimer's disease. The protein is derived from fetal brain tissue and has been shown to cross-react with antibodies that are present in the brains of individuals with Alzheimer's disease.

Recent studies have demonstrated that BPTF is involved in the development and progression of Alzheimer's disease. Studies have shown that BPTF is expressed in the brains of individuals at different stages of Alzheimer's disease, and that it is highly expressed in the brains of individuals with Alzheimer's disease compared to age-matched control individuals.

The potential drug target for BPTF is its role in the development and progression of Alzheimer's disease. By targeting BPTF with a drug, researchers hope to reduce the number of neurons that are lost in the brain and slow down the progression of Alzheimer's disease.

One of the challenges in studying BPTF is its high level of expression in the brain. While it is possible to detect BPTF in the brains of individuals with Alzheimer's disease using antibodies, it is difficult to quantify the level of the protein. This is because BPTF is expressed in a large amount in the brain, and the level of the protein can vary depending on the stage of the disease.

Another challenge is the difficulty of studying a protein that is expressed in the brain. Because the brain is a complex and dynamic system, it is difficult to study the effects of a drug on BPTF without also studying the effects on the brain as a whole. This is why researchers have been unable to determine the exact mechanisms by which BPTF contributes to the development and progression of Alzheimer's disease.

Despite these challenges, researchers are continuing to study BPTF as a potential drug target for Alzheimer's disease. They are using various techniques, such as live-cell imaging and biochemical assays, to study the effects of drugs on BPTF expression in the brain. They are also using animal models to study the effects of drugs on the progression of Alzheimer's disease.

In conclusion, BPTF is a protein that is expressed in the brain and has been identified as a potential drug target for Alzheimer's disease. While there are currently no FDA-approved drugs that target BPTF, researchers are continuing to study the protein and its role in the development and progression of Alzheimer's disease. By studying BPTF, researchers hope to develop new treatments for this debilitating and progressive disease.

Protein Name: Bromodomain PHD Finger Transcription Factor

Functions: Regulatory subunit of the ATP-dependent NURF-1 and NURF-5 ISWI chromatin remodeling complexes, which form ordered nucleosome arrays on chromatin and facilitate access to DNA during DNA-templated processes such as DNA replication, transcription, and repair (PubMed:14609955, PubMed:28801535). The NURF-1 ISWI chromatin remodeling complex has a lower ATP hydrolysis rate than the NURF-5 ISWI chromatin remodeling complex (PubMed:28801535). Within the NURF-1 ISWI chromatin-remodeling complex, binds to the promoters of En1 and En2 to positively regulate their expression and promote brain development (PubMed:14609955). Histone-binding protein which binds to H3 tails trimethylated on 'Lys-4' (H3K4me3), which mark transcription start sites of active genes (PubMed:16728976, PubMed:16728978). Binds to histone H3 tails dimethylated on 'Lys-4' (H3K4Me2) to a lesser extent (PubMed:16728976, PubMed:16728978, PubMed:18042461). May also regulate transcription through direct binding to DNA or transcription factors (PubMed:10575013)

The "BPTF Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BPTF comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets